Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obese patients with atrial fibrillation are more efficiently protected from thrombosis under warfarin or xabans compared to non-obese patients; a systematic review and Meta-analysis of six randomized controlled trials.
Karatisidis L, Zagoridis K, Mprotsis T, Misidou C, Pentidou A, Vrachiolias G, Bezirgianidou Z, Kontomanolis E, Spanoudakis E. Karatisidis L, et al. Among authors: spanoudakis e. Thromb Res. 2024 Jun;238:88-96. doi: 10.1016/j.thromres.2024.04.022. Epub 2024 Apr 24. Thromb Res. 2024. PMID: 38696925
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Perrot A, Delimpasi S, Spanoudakis E, Frølund U, Belotti A, Oriol A, Moreau P, McFadden I, Xia Q, Arora M, Dimopoulos MA. Perrot A, et al. Among authors: spanoudakis e. Leuk Lymphoma. 2024 Mar 18:1-10. doi: 10.1080/10428194.2024.2322030. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38497533
How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials.
Intzes S, Symeonidou M, Zagoridis K, Pentidou A, Bezirgianidou Z, Papoutselis M, Misidou C, Roumpakis C, Spanoudaki A, Liapis K, Spanoudakis E. Intzes S, et al. Among authors: spanoudakis e. Ann Hematol. 2024 May;103(5):1623-1633. doi: 10.1007/s00277-023-05551-5. Epub 2024 Jan 8. Ann Hematol. 2024. PMID: 38191715
Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study.
Petrakis I, Kontogiorgis C, Nena E, Delimpasi S, Loutsidi NE, Spanoudakis E, Intzes S, Misidou C, Symeonidou M, Giannakoulas N, Constantinidis TC, Terpos E. Petrakis I, et al. Among authors: spanoudakis e. Cancers (Basel). 2023 Dec 14;15(24):5846. doi: 10.3390/cancers15245846. Cancers (Basel). 2023. PMID: 38136391 Free PMC article.
Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies.
Zagoridis K, Karatisidis L, Mprotsis T, Pentidou A, Bezirgianidou Z, Misidou C, Spanoudakis E. Zagoridis K, et al. Among authors: spanoudakis e. Thromb Res. 2023 Nov;231:17-24. doi: 10.1016/j.thromres.2023.09.005. Epub 2023 Sep 21. Thromb Res. 2023. PMID: 37748234
74 results